阿托伐他汀对大脑中动脉支架置入后患者血脂、血清CRP及脑缺血性不良事件的影响

目的:探讨阿托伐他汀对大脑中动脉支架置入后患者血脂、血清C-反应蛋白(CRP)及脑缺血性不良事件的影响。方法:选择本院收治的60例行大脑中动脉支架置入术后的患者,采用随机序号的方式将其分为观察组和对照组各30例,其中对照组给予口服拜阿司匹林和硫酸氢氯吡格雷进行治疗,观察组在对照组基础上加服阿托伐他汀进行治疗,对两组治疗后6个月、12个月时患者血脂、血清C-反应蛋白(CRP)及脑缺血性不良事件发生率进行对比分析。结果:观察组在治疗后6个月时LDL-C、TC、TG及CRP含量与治疗前和对照组比较显著下降,比较差异均有统计学意义(P0.05);观察组患者在治疗后的12个月时LDL-C、TC、TG及CRP含量亦明显低于治疗前和对照组,比较差异均有统计学意义(P0.05);观察组不良事件发生率为10%,明显低于对照组不良事件发生率的30%,两组比较差异有统计学意义(P0.05)。结论:阿托伐他汀对不仅可有效改善大脑中动脉支架置入术后患者的血脂、血清C-反应蛋白(CRP)的各项指标水平,而且还能有效的降低脑缺血性不良事件的发生。

Effects of Atorvastatin on the Blood Lipids, SerumCRP and Cerebral Ischemic Adverse Events of Patients with Middle Cerebral Artery Stenting

Objective:To investigate the effects of atorvastatin on the blood lipids, serum C- reactive protein (CRP) and cerebral ischemic adverse events of patients with middle cerebral artery stenting.Methods:60 cases of patients with middle cerebral artery stenting were selected and were divided into observation group(n=30) and control group(n=30) via random number approach, the control group received oral Aspirin chlorine and hydrogen sulfate clopidogrel treatment while the observation group were served basic treatment as the control group and the additional treatment with atorvastatin. The blood lipids, serum C- reactive protein (CRP), and the incidence of cerebral ischemic adverse events were analyzed 6 months and 12 months after treatment.Results:The LDL-C, TC, TG and CRP levels of the observation group after 6 months of treatment significantly decreased compared with pre-treatment and the control group, and the differences were statistically significant (P<0.05); The LDL-C,TC,TG and CRP levels of the observation group after 12 months of treatment was also significantly decreased compared with pre-treatment and the control group, the differences were both statistically significant (P<0.05); The incidence of adverse events in observation group was 10%, significantly lower than that (30%) in the control group, the difference was statistically significant (P<0.05).Conclusion:The atorvastatin can not only effectively improve blood lipids, serum indicators of C-reactive protein (CRP) of patients with middle cerebral artery stenting, but also effectively reduce the brain ischemic adverse events.